Antihypertensive drug class ATC Codes Combinations. 1. Alpha-receptor blockers C02 CA - 2. Beta-blockers C07A C07F

NEUROLOGY/2015/707133 Table e-1. A list of antihypertensive drugs and their ATC codes Antihypertensive drug class ATC Codes Combinations C02 CA -...
Author: Sophia Phillips
21 downloads 2 Views 223KB Size
NEUROLOGY/2015/707133

Table e-1. A list of antihypertensive drugs and their ATC codes Antihypertensive drug class

ATC Codes

Combinations

C02 CA

-

C07A

C07F

C08CA

C08G

C08D, C08E

C08DA51

C03A, C03AX

C03EA

C03CA

C03EB

7. Potassium-sparing diuretics

C03D

-

8. Angiotensin converting enzyme inhibitors

C09A

C09B

9. Angiotensin-2 receptor blockers

C09C

C09D

1. Alpha-receptor blockers 2. Beta-blockers 3. Calcium channel blockers - dihydropyridines 4. Calcium channel blockers - non-dihydropyridines 5. Thiazide diuretics 6. Loop diuretics

ATC codes can be found at http://www.whocc.no/atc_ddd_index/?code=C Accessed 26th February 2016; World Health Organization. Guidelines for ATC classification and DDD assignment. Oslo, Norway: Norwegian Institute of Public Health, 2002

1

NEUROLOGY/2015/707133

Table e-2. Table of comorbidity prevalence in each drug class Antihypertensive drug class

CVD %

Arrhythmia %

DM %

CKD %

HF %

8.2

23.1*

32.7***

30.6***

10.9

2. Beta-blockers

25.1***

26.2****

18.9***

22.2***

14.4***

3. Calcium channel blockers - dihydropyridines

22.6***

17.5

21.0**

22.9**

13.7**

4. Calcium channel blockers - non-dihydropyridines

27.3***

28.8***

14.1

18.2

21.7***

4.1

17.8

21.9**

24.7**

2.7*‡

6. Loop diuretics

28.4***

35.1***

36.5***

42.6***

42.6***

7. Potassium-sparing diuretics

6.3**‡

19.7***

21.0**

31.4***

13.4**

8. Angiotensin converting enzyme inhibitors

18.3***

23.0***

24.2***

23.9***

18.2***

13.0

19.5*

17.9*

23.9**

10.6

1. Alpha-receptor blockers

5. Thiazide diuretics

9. Angiotensin-2 receptor blockers

CVD, cardiovascular disease; DM, diabetes; CKD, chronic kidney disease; HF heart failure; Significantly higher prevalence compared to non-users of antihypertensive drug class *p